{"id":481924,"date":"2020-04-30T11:12:01","date_gmt":"2020-04-30T11:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=481924"},"modified":"2020-04-30T11:12:01","modified_gmt":"2020-04-30T11:12:01","slug":"fibrodysplasia-ossificans-progressiva-market-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/fibrodysplasia-ossificans-progressiva-market-insights-epidemiology-and-market-forecast2030_481924.html","title":{"rendered":"Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2030"},"content":{"rendered":"
\"Fibrodysplasia<\/a><\/div>\n

DelveInsight has launched a new report on Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2030<\/p>\n

DelveInsight’s Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Fibrodysplasia Ossificans Progressiva (FOP) , historical and forecasted epidemiology as well as the Fibrodysplasia Ossificans Progressiva (FOP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The Fibrodysplasia Ossificans Progressiva (FOP) market report provides current treatment practices, emerging drugs, Fibrodysplasia Ossificans Progressiva (FOP) market share of the individual therapies, current and forecasted Fibrodysplasia Ossificans Progressiva (FOP) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Fibrodysplasia Ossificans Progressiva (FOP) treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Fibrodysplasia ossificans progressiva (FOP) <\/strong>is a disorder in which muscle and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside the skeleton (extra-skeletal or heterotopic bone) that constrains movement. This process generally becomes noticeable in early childhood, starting with the neck and shoulders, and proceeding down the body and into the limbs.<\/p>\n

\"\"<\/p>\n

Click Here- <\/strong>Free sample page<\/a><\/p>\n

Epidemiology<\/strong><\/p>\n

The Fibrodysplasia Ossificans Progressiva (FOP) epidemiology division provide insights about historical and current Fibrodysplasia Ossificans Progressiva (FOP) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  <\/p>\n

Report key facts-<\/strong><\/p>\n

1.<\/strong> Frederick et al. conducted a study in Philadelphia, United States, titled “Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis,” which stated that the worldwide prevalence of FOP is approximately 1 in 2,000,000. Phenotypic variability in the timing and intensity of flare-ups can be a diagnostic criterion for FOP without evidence of ethnic, racial, gender, or geographic predisposition.<\/p>\n

2. According to the European Conference on Rare Diseases, FOP has a prevalence rate of 0.08 per 100,000 people.<\/p>\n

3. As per the Delveinsight’sanalysis<\/strong>, the total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) in the seven major markets was found to be 630<\/strong> in 2017. In the United States total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) was found to be 293<\/strong> in 2017.<\/p>\n

 Some of key major companies are working on this disease that are given below-<\/strong><\/p>\n

1. Ipsen Pharmaceuticals<\/p>\n

2. Regeneron Pharmaceuticals<\/p>\n

3. BioCryst Co.<\/p>\n

Name of drugs covered which are given below-<\/strong><\/p>\n

1. Palovarotene<\/p>\n

2. Garetosmab (REGN2477)<\/p>\n

3. BLU-782<\/p>\n

Table of content<\/a><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary of Fibrodysplasia Ossificans Progressiva (FOP)<\/p>\n

3. Competitive Intelligence Analysis for Fibrodysplasia Ossificans Progressiva (FOP)<\/p>\n

4. Fibrodysplasia Ossificans Progressiva (FOP) : Market Overview at a Glance<\/p>\n

4.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Share (%) Distribution in 2017<\/p>\n

4.2. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Share (%) Distribution in 2030<\/p>\n

5. Fibrodysplasia Ossificans Progressiva (FOP) : Disease Background and Overview<\/p>\n

5.1. Introduction<\/p>\n

5.2. Sign and Symptoms <\/p>\n

5.3. Pathophysiology <\/p>\n

5.4. Risk Factors <\/p>\n

5.5. Diagnosis <\/p>\n

6. Patient Journey<\/p>\n

7. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology and Patient Population<\/p>\n

7.1. Epidemiology Key Findings<\/p>\n

7.2. Assumptions and Rationale: 7MM<\/p>\n

7.3. Epidemiology Scenario: 7MM<\/p>\n

7.3.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in the 7MM (2017-2030)<\/p>\n

7.4. United States Epidemiology<\/p>\n

7.4.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in the United States (2017-2030)<\/p>\n

7.5. EU-5 Country-wise Epidemiology<\/p>\n

7.5.1. Germany Epidemiology<\/p>\n

7.5.1.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Germany (2017-2030)<\/p>\n

7.5.2. France Epidemiology<\/p>\n

7.5.2.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in France (2017-2030)<\/p>\n

7.5.3. Italy Epidemiology<\/p>\n

7.5.3.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Italy (2017-2030)<\/p>\n

7.5.4. Spain Epidemiology<\/p>\n

7.5.4.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Spain (2017-2030)<\/p>\n

7.5.5. United Kingdom Epidemiology<\/p>\n

7.5.5.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n

7.5.6. Japan Epidemiology<\/p>\n

7.5.6.1. Fibrodysplasia Ossificans Progressiva (FOP) Epidemiology Scenario in Japan (2017-2030)<\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

8.1. Fibrodysplasia Ossificans Progressiva (FOP) Treatment and Management<\/p>\n

8.2. Fibrodysplasia Ossificans Progressiva (FOP) Treatment Algorithm <\/p>\n

9. Unmet Needs<\/p>\n

10. Key Endpoints of Fibrodysplasia Ossificans Progressiva (FOP) Treatment<\/p>\n

11. Marketed Products<\/p>\n

11.1. List of Marketed Products in the 7MM<\/p>\n

11.2. Drug Name: Company Name<\/p>\n

11.2.1. Product Description<\/p>\n

11.2.2. Regulatory Milestones<\/p>\n

11.2.3. Other Developmental Activities<\/p>\n

11.2.4. Pivotal Clinical Trials<\/p>\n

11.2.5. Summary of Pivotal Clinical Trial<\/p>\n

12. Emerging Therapies<\/p>\n

12.1. Key Cross<\/p>\n

12.2. Drug Name: Company Name<\/p>\n

12.2.1. Product Description<\/p>\n

12.2.2. Other Developmental Activities<\/p>\n

12.2.3. Clinical Development<\/p>\n

12.2.4. Safety and Efficacy<\/p>\n

12.2.5. Product Profile<\/p>\n

13. Fibrodysplasia Ossificans Progressiva (FOP) : Seven Major Market Analysis<\/p>\n

13.1. Key Findings<\/p>\n

13.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size in 7MM<\/p>\n

13.3. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in the 7MM<\/p>\n

14. Attribute analysis<\/p>\n

15. 7MM: Market Outlook<\/p>\n

15.1. United States: Market Size<\/p>\n

15.1.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in the United States<\/p>\n

15.1.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in the United States<\/p>\n

15.2. EU-5 countries: Market Size and Outlook<\/p>\n

15.3. Germany Market Size<\/p>\n

15.3.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in Germany<\/p>\n

15.3.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in Germany<\/p>\n

15.4. France Market Size<\/p>\n

15.4.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in France<\/p>\n

15.4.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in France<\/p>\n

15.5. Italy Market Size<\/p>\n

15.5.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in Italy<\/p>\n

15.5.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in Italy<\/p>\n

15.6. Spain Market Size<\/p>\n

15.6.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in Spain<\/p>\n

15.6.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in Spain<\/p>\n

15.7. United Kingdom Market Size<\/p>\n

15.7.1. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in the United Kingdom<\/p>\n

15.7.2. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in the United Kingdom<\/p>\n

15.8. Japan Market Outlook<\/p>\n

15.8.1. Japan Market Size<\/p>\n

15.8.2. Fibrodysplasia Ossificans Progressiva (FOP) Total Market Size in Japan<\/p>\n

15.8.3. Fibrodysplasia Ossificans Progressiva (FOP) Market Size by Therapies in Japan<\/p>\n

16. Access and Reimbursement Overview of Fibrodysplasia Ossificans Progressiva (FOP)<\/p>\n

17. KOL Views<\/p>\n

18. Market Drivers<\/p>\n

19. Market Barriers<\/p>\n

20. Appendix<\/p>\n

20.1. Bibliography<\/p>\n

20.2. Report Methodology<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

23. About<\/strong> DelveInsight<\/a><\/p>\n

Why should you buy this report?<\/strong><\/p>\n